Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Public ClinicalTrials.gov record NCT05742802. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of Exacerbations (PROSPERO).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.
Study identification
- NCT ID
- NCT05742802
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,713 participants
Conditions and interventions
Conditions
Interventions
- Tozorakimab 1 Combination Product
- Tozorakimab 2 Combination Product
- Placebo Combination Product
Combination Product
Eligibility (public fields only)
- Age range
- 40 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 6, 2023 (Actual)
- Primary completion
- Feb 26, 2026 (Actual)
- Completion
- May 27, 2026 (Actual)
- Last update posted
- Jun 25, 2026
2023 – 2026
United States locations
- U.S. sites
- 46
- U.S. states
- 26
- U.S. cities
- 46
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Sheffield | Alabama | 35660 | — |
| Research Site | Tempe | Arizona | 85283 | — |
| Research Site | Lincoln | California | 95648 | — |
| Research Site | Newport Beach | California | 92663 | — |
| Research Site | Northridge | California | 91324 | — |
| Research Site | Boynton Beach | Florida | 33435 | — |
| Research Site | Cape Coral | Florida | 33990 | — |
| Research Site | Ormond Beach | Florida | 32174 | — |
| Research Site | Pensacola | Florida | 32503 | — |
| Research Site | Plantation | Florida | 33324 | — |
| Research Site | Tampa | Florida | 33607 | — |
| Research Site | Winter Park | Florida | 32789 | — |
| Research Site | Evergreen Park | Illinois | 60805 | — |
| Research Site | Normal | Illinois | 61761 | — |
| Research Site | Greenwood | Indiana | 46143 | — |
| Research Site | Kansas City | Kansas | 66160 | — |
| Research Site | Bowling Green | Kentucky | 42101 | — |
| Research Site | Baton Rouge | Louisiana | 70836 | — |
| Research Site | Zachary | Louisiana | 70791 | — |
| Research Site | Baltimore | Maryland | 21224 | — |
| Research Site | White Marsh | Maryland | 21162 | — |
| Research Site | North Dartmouth | Massachusetts | 02747 | — |
| Research Site | Farmington Hills | Michigan | 48336 | — |
| Research Site | Grand Rapids | Michigan | 49546 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Buffalo | New York | 14203 | — |
| Research Site | Durham | North Carolina | 27705 | — |
| Research Site | Gastonia | North Carolina | 28054 | — |
| Research Site | Fargo | North Dakota | 58104 | — |
| Research Site | Toledo | Ohio | 43617 | — |
| Research Site | Tulsa | Oklahoma | 74133 | — |
| Research Site | DuBois | Pennsylvania | 15801 | — |
| Research Site | Philadelphia | Pennsylvania | 19140 | — |
| Research Site | Pittsburgh | Pennsylvania | 15213 | — |
| Research Site | Sayre | Pennsylvania | 18840 | — |
| Research Site | Rock Hill | South Carolina | 29732 | — |
| Research Site | Franklin | Tennessee | 37067 | — |
| Research Site | Amarillo | Texas | 79106 | — |
| Research Site | Boerne | Texas | 78006 | — |
| Research Site | Kingwood | Texas | 77339 | — |
| Research Site | McKinney | Texas | 75069 | — |
| Research Site | Tomball | Texas | 77375 | — |
| Research Site | Colchester | Vermont | 05446 | — |
| Research Site | Williamsburg | Virginia | 23188 | — |
| Research Site | Cudahy | Wisconsin | 53110 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 289 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05742802, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 25, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05742802 live on ClinicalTrials.gov.